Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | CA3 | P07451 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA6 | P23280 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883464 | 1.00 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL31219712 | 0.93 | ACHE (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2148897 | 0.81 | CA2 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL486801 | 0.76 | HTR6 (0.46) | CA1CA2CA12CA9CA14 | |
| SCHEMBL5501401 | 0.76 | CA2 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL24008845 | 0.75 | GAA (0.48) | CA1CA2CA12CA9CA3 | |
| SCHEMBL17680474 | 0.75 | CA2 (0.45) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2345848 | 0.74 | ACHE (0.51) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2632975 | 0.74 | DDIT3 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2820495 | 0.73 | ALDH1A1 (0.58) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| EP-2170839-B1 | ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS | BAYER IP GMBH (DE) | 2015-09-09 | — | — | EP | disclosed |
| EP-2170839-B1 | ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS | BAYER IP GMBH (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-8642611-B2 | Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642611-B2 | Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642611-B2 | Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2022785-A1 | Alkynylpyrimidines as Tie2 kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-11 | — | — | EP | disclosed |
| EP-2022785-A1 | Alkynylpyrimidines as Tie2 kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008155140-A1 | ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | CA1 4347/4885CA2 1063/4885CA12 2931/4885 |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | CDK1, CDK9, CDK6 | CA1 2927/4885CA2 3695/4885CA12 3998/4885 |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | TYMS, DPYD, DHFR | CA1 3922/4885CA2 4328/4885CA12 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.